22087-22-5

Usage

Uses

Used in Organic Synthesis:
[2-(4-CHLORO-PHENYL)-OXAZOL-4-YL]-METHANOL is used as a building block in organic synthesis for the preparation of biologically active compounds. Its unique structure and functional groups allow for the creation of a variety of molecules with potential applications in different fields.
Used in Pharmaceutical Research:
In Pharmaceutical Research, [2-(4-CHLORO-PHENYL)-OXAZOL-4-YL]-METHANOL is used as a key intermediate for the development of new drugs. Its structural features and functional groups make it a valuable component in the design and synthesis of pharmaceutical compounds with potential therapeutic effects.
Used in Medicinal Chemistry:
[2-(4-CHLORO-PHENYL)-OXAZOL-4-YL]-METHANOL is used in medicinal chemistry for the exploration of its potential applications in drug development. Its structural characteristics and functional groups may contribute to the discovery of new therapeutic agents.
Used in Drug Development:
In Drug Development, [2-(4-CHLORO-PHENYL)-OXAZOL-4-YL]-METHANOL is used as a starting material for the synthesis of novel drug candidates. Its potential applications in this field are currently under investigation, with the aim of identifying its role in the creation of effective and safe medications.
Note: Since the provided materials do not specify particular industries or reasons for the applications, the uses listed are general and based on the compound's potential roles in related fields. Further research and development would be required to pinpoint specific applications and industries.

Upstream product

• 104-88-1 4-chlorobenzaldehyde 
• 300800-07-1 methyl 2-(4-chlorophenyl)-1,3-oxazole-4-carboxylate 
• 619-56-7 4-chlorobenzamide 
• 22091-36-7 4-chloromethyl-2-(4-chlorophenyl)oxazole 

Downstream Products

• 1107662-79-2 2-Amino-6-{[2-(4-chlorophenyl)-1,3-oxazol-4-yl]methoxy}-4-[4-(2-hydroxyethoxy)phenyl]-pyridine-3,5-dicarbonitrile 
• 1107663-70-6 2-Amino-6-{[2-(4-chlorophenyl)-1,3-oxazol-4-yl]methoxy}-4-(4-{[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy}phenyl)pyridine-3,5-dicarbonitrile 
• 1107662-78-1 2-Amino-6-{[2-(4-chlorophenyl)-1,3-oxazol-4-yl]methoxy}-4-(4-{[(2R)-2,3-dihydroxypropyl]oxy}phenyl)pyridine-3,5-dicarbonitrile 
• 1198212-13-3 2-{[2-(4-Chlorophenyl)-1,3-oxazol-4-yl]methoxy}-4-[4-(2-hydroxyethoxy)phenyl]-6-methoxypyridine-3,5-dicarbonitrile 
• 59398-91-3 2-(4-chloro-phenyl)-oxazole-4-carbaldehyde 
• 22091-36-7 4-chloromethyl-2-(4-chlorophenyl)oxazole 
• 1325717-69-8 Methyl 2-(4-chlorophenyl)-4-(hydroxymethyl)-1,3-oxazole-5-carboxylate 
• 1325717-68-7 Methyl 2-(4-chlorophenyl)-4-[(methoxymethoxy)methyl]-1,3-oxazole-5-carboxylate 
• 1325717-58-5 2-(4-Chlorophenyl)-4-[(methoxymethoxy)methyl]-1,3-oxazole-5-carboxylic acid 
• 1325717-56-3 2-(4-Chlorophenyl)-4-[(methoxymethoxy)methyl]-1,3-oxazole-5-carbaldehyde 
• 1325717-55-2 2-(4-Chlorophenyl)-4-[(methoxymethoxy)methyl]-1,3-oxazole 
• 36841-60-8 [5-bromo-2-(4-chloro-phenyl)-oxazol-4-yl]-methanol 

Relevant academic research and scientific papers

2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS

The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X1 and X2 are independently, at each occurrence, CR5 or N; Y is C1-C6 alkylene, wherein alkylene is optionally substituted with one to two C1-C3 alkyl groups; R1 is selected from the group consisting of hydrogen, halogen, C1-C6 alkoxy, -NH2, -NHR6, -NR7R8 and -NH-(R9)n-R10, n being 0 or 1; R2 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, -NH2, -NHR6, - NR7R8 and -NH-(R9)n-R10; R3 is selected from the group consisting of hydrogen, hydroxyl, OR11, -NR7R8, C1-C6 alkoxy, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C3 haloalkyl, -C(O)NHR11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Ra groups; and R4 is selected from the group consisting of -NH2, -N(R12)(V)pR13, - NH(V)p-OR14, -NHC(O)R15, and groups of formula la shown below, and their use in the treatment of diseases, in particular inflammatory diseases, cancer, stroke and/or Alzheimer's disease.

Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB

A high-throughput screening effort on 45,000 compounds resulted in the discovery of a disubstituted oxazole as a new structural class inhibitor of Mycobacterium tuberculosis (Mtb). In order to improve the activity and investigate the SAR of this scaffold, a series of disubstituted azole analogues have been designed and synthesized. The newly synthesized compounds 1a-y were evaluated for their in vitro anti-TB activity versus replicating, multi- and extensive drug resistant Mtb strains. All the compounds, except 1o, 1p and 1q, showed potent anti-TB activity with MIC of 1-64 mg/L. The test of broad spectrum panel revealed that this series are specific to Mtb. The cytotoxicity assessment indicated that the compounds were not cytotoxic against HEK 293 cells. The compounds could have a novel mechanism to anti-Mtb as they can inhibit drug sensitive and drug resistant Mtb.

2-ALKOXY-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE

The present application relates to novel 2-alkoxy-substituted dicyanopyridines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders.

SUBSTITUTED ARYLOXAZOLES AND THEIR USE

The present application relates to novel substituted aryloxazole derivatives, a method for the production thereof, the use thereof for the treatment and/or prophylaxis of diseases and the use thereof for the production of drugs for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.